HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Increase in outflow facility with unoprostone treatment in ocular hypertensive patients.

AbstractOBJECTIVE:
To determine the mechanism by which 0.15% unoprostone isopropyl reduces intraocular pressure (IOP) by studying 33 patients with ocular hypertension or primary open-angle glaucoma.
METHODS:
At baseline, IOP was determined by pneumatonometry, aqueous flow and outflow facility by fluorophotometry, episcleral venous pressure by venomanometry, and uveoscleral outflow by mathematical calculation. Unoprostone was administered to one eye and placebo to the fellow eye of each patient twice daily in a randomized masked fashion. In patients who demonstrated an IOP reduction of 3 mm Hg or more in either eye on day 5 +/- 1 (n = 29), determinations were repeated on that day and on day 28 +/- 2. Treated eyes were compared with control eyes, and treatment days were compared with baseline by paired t tests.
RESULTS:
Compared with baseline, unoprostone significantly (P<.001) reduced IOP by a mean +/- SEM of 5.6 +/- 0.4 mm Hg and 4.8 +/- 0.6 mm Hg on days 5 and 28, respectively. The change from baseline with unoprostone was significantly (P<.001) greater than with placebo by 2.8 +/- 0.4 mm Hg on day 5 and by 3.2 +/- 0.5 mm Hg on day 28. Compared with baseline, unoprostone significantly (P</=.001) increased outflow facility by 0.05 +/- 0.01 and 0.08 +/- 0.02 microL.min(-1).mm Hg(-1) on days 5 and 28, respectively. The baseline-adjusted between-treatment differences were significant (P</=.04) on day 28 (0.06 +/- 0.02 microL.min(-1).mm Hg(-1)). Other measures were not different from placebo.
CONCLUSION:
In responsive patients, unoprostone decreased IOP by increasing outflow facility.
AuthorsCarol B Toris, Guilin Zhan, Carl B Camras
JournalArchives of ophthalmology (Chicago, Ill. : 1960) (Arch Ophthalmol) Vol. 122 Issue 12 Pg. 1782-7 (Dec 2004) ISSN: 0003-9950 [Print] United States
PMID15596580 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antihypertensive Agents
  • Ophthalmic Solutions
  • isopropyl unoprostone
  • Dinoprost
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antihypertensive Agents (administration & dosage, therapeutic use)
  • Aqueous Humor (metabolism)
  • Dinoprost (administration & dosage, analogs & derivatives, therapeutic use)
  • Double-Blind Method
  • Female
  • Fluorophotometry
  • Glaucoma, Open-Angle (drug therapy, metabolism)
  • Humans
  • Intraocular Pressure (drug effects)
  • Male
  • Middle Aged
  • Ocular Hypertension (drug therapy, metabolism)
  • Ophthalmic Solutions
  • Tonometry, Ocular

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: